The multi-year agreement will enable Pfizer to gain access to the database, which includes information on more than 3,200 genes, along with 852 immunohistochemistry reports with localization information on more than 400 potential drug targets.
Both LifeSpan and Pfizer said they would add targets to the database over time.
Financial details were not discussed.